SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma gets USFDA nod for Tamsulosin HCL Capsules and Pediatric

04 May 2013 Evaluate

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Tamsulosin Hydrochloride Capsules USP 0.4mg (ANDA 202433) and Clindamycin Palmitate Hydrochloride for Oral Solution USP (Pediatric), 75mg (base)/5mL (ANDA 202409). The products will be launched soon.

Tamsulosin Hydrochloride Capsules USP 0.4mg is the generic equivalent of Boehringer Ingelheim Pharmaceuticals’ Flomax Capsules, 0.4mg and is indicated for the treatment of symptoms of an enlarged prostate (Benign Prostatic Hyperplasia - BPH) in men. The market size of the product is estimated to be $244 million for the twelve months ending September 2012 according to IMS.

Clindamycin Palmitate Hydrochloride for Oral Solution USP (Pediatric), 75mg (base)/5mL is the generic equivalent of Pharmacia & Upjohn’s Cleocin Pediatric for oral solution, 75mg (base)/5mL and is indicated for the treatment of serious infections caused by susceptible anaerobic bacteria in infants. The market size of the product is estimated to be $57 million for the twelve months ending September 2012 according to IMS. Aurobindo now has a total of 190 ANDA approvals (163 Final approvals including 4 from Aurolife Pharma LLC and 27 tentative approvals) from USFDA.

Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.

Aurobindo Pharma Share Price

1385.65 -0.45 (-0.03%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×